Passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic metabolic disorders

Agios (NASDAQ: AGIO) is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic metabolic disorders through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging the company’s knowledge of metabolism, biology and genomics.

Year Invested: 2008
Location: Cambridge, Mass.

Recent News

March 13, 2017
Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene

March 1, 2017
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation

February 28, 2017
Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017

Read More News

Associated Team Members

Kevin Starr

Craig Muir
Partner/Chief Technology Officer

Cary Pfeffer, M.D.